The obesity epidemic is steadily increasing worldwide, and high body mass index (BMI)
is a major risk factor for cardiovascular diseases, diabetes, hypertension, musculoskeletal
disorders, and also some cancers [
[1]
]. Diets are generally unsuccessful [
World Health Organization. Obesity and overweight. 2015. [cited 2016 March 21]. Available from: 〈http://www.who.int/mediacentre/factsheets/fs311/en/〉.
[2]
]. Bariatric surgery is today the main treatment for severe obesity [
[3]
]. There is a strong interest in finding less invasive methods [
[4]
] and whether that preoperative weight loss improves surgery outcomes [
[2]
] and reduces perioperative complications [
[5]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgery for Obesity and Related DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
World Health Organization. Obesity and overweight. 2015. [cited 2016 March 21]. Available from: 〈http://www.who.int/mediacentre/factsheets/fs311/en/〉.
- A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery.Ann Surg. 2010; 251: 236-243
- The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes.Surg Obes Relat Dis. 2013; 9: 482-484
- The feasibility of delivering a duodenal-jejunal bypass liner (EndoBarrier) endoscopically with patients under conscious sedation.Surg Endosc. 2014; 28: 325-330
- Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.Gastrointest Endosc. 2010; 71: 976-982
- Duodenal- jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity.Surg Innov. 2007; 14: 275-278
- Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes.Diabetes Technol Ther. 2009; 11: 725-732
- Radiographic appearance of endoscopic duodenal-jejunal bypass liner for treatment of obesity and type 2 diabetes.Surg Obes Relat Dis. 2009; 5: 371-374
- Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies.BMJ Open. 2013; 3: e003417
- First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve.Surg Obes Relat Dis. 2008; 4: 55-59
- Minimally invasive treatment of a duodenal perforation associated with the EndoBarrier duodenal-jejunal bypass liner.Endosc. 2014; 46: E171-E172
- Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery.Surg Endosc. 2009; 23: 650-656
- Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.Ann Surg. 2012; 255: 1080-1085
ENDO Trial Placed on Enrollment Hold. GI Dynamics. March 5, 2015 [cited 2016 Apr 29]. Available from: 〈http://www.gidynamics.com/media-press-release.php?id=139〉.
Article info
Publication history
Published online: February 23, 2016
Accepted:
February 18,
2016
Received in revised form:
February 18,
2016
Received:
January 29,
2016
Identification
Copyright
© 2016 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
